Trials / Completed
CompletedNCT04493502
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered IV |
| DRUG | LY3041658 | Administered IV |
Timeline
- Start date
- 2020-08-26
- Primary completion
- 2022-03-15
- Completion
- 2022-10-13
- First posted
- 2020-07-30
- Last updated
- 2023-04-28
- Results posted
- 2023-04-28
Locations
20 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04493502. Inclusion in this directory is not an endorsement.